- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04228276
Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation (VA-StARTS)
February 8, 2024 updated by: VA Office of Research and Development
The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD).
Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment.
rTMS may be a promising treatment option for SUD.
In this study, we will demonstrate the feasibility of applying rTMS to Veterans with SUD, examine the efficacy of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jong H Yoon, MD
- Phone Number: (650) 493-5000
- Email: jhyoon1@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1207
- Recruiting
- VA Palo Alto Health Care System, Palo Alto, CA
-
Contact:
- Jong H Yoon, MD
- Phone Number: 650-493-5000
- Email: jhyoon1@stanford.edu
-
Principal Investigator:
- Jong H. Yoon, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- SCID confirmed diagnosis of SUD, severe
- Last use of stimulants >1 and <6 weeks
- Stable medication regimen (no change in dose or agents between 2 weeks prior to the start of and throughout the treatment phase of the study)
- Stable social environment and housing to enable regular attendance at clinic visits.
- Ability to undergo cognitive testing, fMRI scans, and rTMS (no contraindications)
- IQ > 80
- Stable medical health
- Veteran at Palo Alto VA's Addiction Treatment Services
Exclusion Criteria:
- Pregnant or lactating female
- History of prior adverse reaction to TMS
On medications thought to significantly lower seizure threshold, e.g.:
- clozapine
- chlorpromazine
- clomipramine
- bupropion > 400 mg/day
- Use of direct dopaminergic antagonists or agonists
- History of seizures or conditions known to substantially increase risk for seizures
- Implants or medical devices incompatible with TMS
- Acute or unstable chronic medical illness that would affect participation or compliance with study procedures, e.g. unstable angina
Unstable psychiatric symptoms that precludes consistent participation in the study, e.g.:
- active current suicidal intent or plan
- severe psychosis
- Inability to undergo fMRI scan, e.g. claustrophobia, presence of ferromagnetic objects in subject's body
- Other substance use disorder not in sustained remission
- Chronic or recurring Axis I psychiatric condition preceding SUD other than PTSD
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active rTMS
Receive active rTMS
|
rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions.
The intervention (active and sham) will be administered in 8 sessions across 2 weeks.
The brain region targeted is the dorsolateral prefrontal cortex.
|
Sham Comparator: Sham rTMS
Receive sham rTMS
|
rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions.
The intervention (active and sham) will be administered in 8 sessions across 2 weeks.
The brain region targeted is the dorsolateral prefrontal cortex.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse rate
Time Frame: 3 months after last rTMS treatment
|
Rate of stimulant use relapse and duration of abstinence compared between active vs. sham rTMS groups
|
3 months after last rTMS treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occupational/role functioning
Time Frame: Within 1 week before rTMS treatment, midpoint during rTMS treatment, within 1 week after rTMS treatment, and 3 months following rTMS treatment
|
Occupational/role functioning and changes in functioning compared between active vs. sham rTMS groups
|
Within 1 week before rTMS treatment, midpoint during rTMS treatment, within 1 week after rTMS treatment, and 3 months following rTMS treatment
|
Rest/activity cycles
Time Frame: During 2-week rTMS treatment and for 1 month following treatment
|
Actigraphy will be conducted to examine rest/activity cycles during and following rTMS treatment.
Changes will be compared between active and sham rTMS groups, and correlated with improvements in SUD.
|
During 2-week rTMS treatment and for 1 month following treatment
|
Reward circuit function and signaling
Time Frame: Within 1 week before and after rTMS treatment
|
Before and after treatment, participants will undergo functional magnetic resonance imaging (fMRI) imaging while completing the Monetary Incentive Delay Task, a validated probe of reward processing circuit function and dysfunction.
Signaling in the substantia nigra will be measured in an individual-subject, "native space" ROI approach as a marker of dopaminergic reward processing function, as well as in voxel-wise, whole-brain exploratory analyses.
Changes in reward function and signaling will be compared between active vs. sham rTMS groups
|
Within 1 week before and after rTMS treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jong H. Yoon, MD, VA Palo Alto Health Care System, Palo Alto, CA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 5, 2021
Primary Completion (Estimated)
April 30, 2024
Study Completion (Estimated)
April 30, 2024
Study Registration Dates
First Submitted
January 7, 2020
First Submitted That Met QC Criteria
January 10, 2020
First Posted (Actual)
January 14, 2020
Study Record Updates
Last Update Posted (Actual)
February 9, 2024
Last Update Submitted That Met QC Criteria
February 8, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D3314-P
- 54458 (Other Identifier: Stanford University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-related Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
VA Office of Research and DevelopmentRecruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University of Southern CaliforniaNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on Repetitive transcranial magnetic stimulation (rTMS)
-
Centre Hospitalier Universitaire de NiceCompletedPost-traumatic Stress DisorderFrance
-
MGH Institute of Health ProfessionsNational Institute on Deafness and Other Communication Disorders (NIDCD)Recruiting
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Krystal Parker, PhDRecruitingDepression | Schizophrenia | Parkinson Disease | Bipolar Disorder | Autism Spectrum DisorderUnited States
-
Brigham and Women's HospitalBeth Israel Deaconess Medical Center; Mclean HospitalNot yet recruitingObesity | Appetitive BehaviorUnited States
-
Yi YangNot yet recruiting
-
Mclean HospitalNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterRecruitingSchizophrenia | Schizo Affective DisorderUnited States
-
Tehran University of Medical SciencesUnknownBorderline Personality Disorder
-
Kaohsiung Veterans General Hospital.RecruitingBipolar II Disorder, Most Recent Episode Major DepressiveTaiwan
-
University of AlbertaRecruitingDepressive Disorder, Treatment-ResistantCanada